Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
CUPR · Price history
Price at last available close
$1.86
−$0.15 (-7.46%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
How they make money
Cuprina Holdings generates revenue primarily through the manufacturing, marketing, and sale of medical devices for chronic wound management, specifically maggot debridement therapy (MDT) products, and cosmeceutical products. The company operates as a biomedical entity that incurs fixed production costs and relies on scaling sales volume to achieve profitability, while also pursuing strategic growth in infertility and medical waste recycling sectors.
Products & services
The company provides medical devices for chronic wound management, including Maggot Debridement Therapy (MDT) products, and various cosmeceutical products.
Brands & revenue mix
Brand for Maggot Debridement Therapy (MDT) products.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- unnamed — The company utilizes various third-party suppliers for raw materials and components required for the manufacturing of its medical devices and cosmeceuticals.Source
Business relationships & partnerships
Strengths
- Specialized focus on chronic wound management and MDT technologySource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2025-12-31.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Total debt increased 296.3% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
23
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
32
Poor
Financial Strength
21
Business Quality / Moat
49
Management
40
Growth Quality
35
Risk / Durability
7
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •Elevated debt risk
- •M&A headline · Oct 2, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for CUPR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CUPR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can CUPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is CUPR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for CUPR to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CUPR's current valuation?
Essential Investment Snapshot
Wall Street Score
23
Market Cap
$5.0M
P/E Ratio
-1.6
EPS
$-1.44
52-Week High
$14.80
52-Week Low
$1.45
Beta
-0.38
Shares Outstanding
2.6M
Total Revenue
$39K
Total Debt
$378K
Dividend
No current dividend
Liquidation Value / Share
$1.55
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CUPR
Detected from reported data — verify before acting.Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
M&A headline · Oct 2, 2026
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on CUPR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Specialized focus on chronic wound management and MDT technology.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Significant operating losses and accumulated deficit.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
23
Sep 17, 2026
Change
-0.7
points
Current Score
23
Oct 1, 2026
Category Changes
CUPR decreased 0.7 points because Asset declined by 7.3 points.
Negative Contributors
- − Asset declined by 7.3 points
Projected Score
Projected Score
27
Projected Change
+4.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.86
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $39K | $38K | $79K | ···· | ···· |
| Cost of Revenue | — | $40K | $40K | $50K | ···· | ···· |
| Gross Profit | — | -$504.84 | -$2K | $29K | ···· | ···· |
| Research & Development | — | $178K | $189K | $131K | ···· | ···· |
| SG&A Expenses | — | $3.4M | $993K | $652K | ···· | ···· |
| Operating Expenses | — | $3.6M | $1.3M | $865K | ···· | ···· |
| EBITDA | — | -$3.6M | -$1.1M | -$778K | ···· | ···· |
| Operating Income | — | -$3.6M | -$1.3M | -$836K | ···· | ···· |
| Interest Expense | — | $12K | $29K | $44K | ···· | ···· |
| Income Before Tax | — | -$3.7M | -$1.2M | -$850K | ···· | ···· |
| Income Tax Expense | — | $0.00 | $41K | $26K | ···· | ···· |
| Net Income | — | -$3.7M | -$1.2M | -$876K | ···· | ···· |
| Basic EPS | — | $-1.44 | $-0.45 | $-0.32 | ···· | ···· |
| Basic Shares | 2.68M | 2.56M | 2.72M | 2.72M | ···· | ···· |
| Diluted Shares | 2.68M | 2.56M | 2.72M | 2.72M | ···· | ···· |
Earnings Summary
Revenue
$39052
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.44
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+89.5%
Cash Change
+2576.8%
Margin Change
-6137.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 3.3%. EPS increased 220.8%. Cash increased 2576.8%. Total debt increased 89.5%. Net income margin declined by 6137.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering
Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Shares Shorted: Short Interest Up 223.6% in September
Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering
Rumor Mill · CUPR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial